A retrospective, observational study evaluating the gastric acid suppression effect on efficacy of erlotinib and gefitinib in patients with non-small-cell lung carcinoma
Latest Information Update: 27 Jul 2016
At a glance
- Drugs Erlotinib (Primary) ; Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 27 Jul 2016 New trial record
- 07 Jun 2016 Results assessing the impact of gastric suppression on progression free survival presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.